Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company

SPIMACO is One of the Largest Saudi Pharma Companies and a Leader in 21 Markets Across the MENA Region

BETHESDA, Md., Aug. 6, 2026 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (the "Company" or "NWBio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that it has entered into a non-binding Memorandum of Understanding (MOU) with the Saudi Pharmaceutical Industries and Medical Appliance Company (SPIMACO) for a collaboration to bring the Company's DCVax®-L products and technology to Saudi Arabia. SPIMACO is one of the largest pharmaceutical companies in Saudi Arabia and a leader in 21 markets across the Middle East North Africa (MENA) region.

The MOU establishes a general framework for discussions for the potential collaboration regarding the approval, commercialization, supply and technology transfer of the Company's DCVax®-L product for glioblastoma brain cancer (Product) in Saudi Arabia (Territory). Over time, the collaboration may expand by mutual agreement to include DCVax-L products for other indications in addition to brain cancer, and may expand to include other territories, such as Gulf Cooperation Council (GCC) countries.

The collaboration is based upon a revenue sharing model. Subject to the execution of definitive agreements, the parties currently contemplate that SPIMACO would be responsible for interfacing with the Saudi Food and Drug Authority (SFDA), including the application for approval of DCVax-L for glioblastoma, and would be expected to serve as the Company's commercial partner responsible for marketing, sales and distribution. The Company will provide the data and documentation for regulatory purposes, and will provide scientific support. The Company will also produce and supply the DCVax-L products. The Company retains all ownership of all intellectual property.

The MOU also recognizes that localization and technology transfer are key parts of the contemplated collaboration. Under its Vision 2030 national plan, Saudi Arabia is becoming a regional and global hub for life sciences and biotechnology. Accordingly, the MOU provides for the parties to negotiate a license and technology transfer arrangement that will lead to enablement of localized manufacturing of DCVax-L in Saudi Arabia. The parties will negotiate separate agreements for that stage.

Prof. Ahmed Aljedai, Vice Chairman and Managing Director of SPIMACO, said: "Strategic partnerships are a key enabler of SPIMACO's long-term growth and transformation. This Memorandum of Understanding with Northwest Biotherapeutics reflects our commitment to collaborating with global innovators to strengthen our capabilities in biopharmaceuticals, advance innovation and knowledge transfer, and support the continued development of Saudi Arabia's biotechnology ecosystem in line with the ambitions of Vision 2030 and our commitment to strengthening pharmaceutical security."

Linda Powers, the Company's CEO, commented: "We are excited to join forces with SPIMACO as a leader in Saudi Arabia's building of a major global biotechnology hub. SPIMACO has been developing state-of-the-art facilities and acquiring state-of-the-art technologies for this hub. We are gratified that SPIMACO sees the important potential of DCVax technologies, and we look forward to contributing to these developments."

About SPIMACO

Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) is one of the largest pharmaceutical companies in Saudi Arabia and a leading pharmaceutical manufacturer across the Middle East and North Africa. Since its establishment in 1986, SPIMACO has been committed to developing, manufacturing, and supplying high-quality pharmaceutical products while advancing innovation, supporting pharmaceutical security, and expanding its capabilities in specialty pharmaceuticals and biopharmaceuticals. Through strategic partnerships and continuous investment in research, technology, and advanced manufacturing, SPIMACO continues to support the Kingdom's healthcare priorities and contribute to the development of a competitive life sciences sector.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing personalized immunotherapy products that are designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company has a broad platform technology for DCVax^® dendritic cell-based vaccines. The Company's lead program involves DCVax^®-L treatment for glioblastoma (GBM). GBM is the most aggressive and lethal form of primary brain cancer, and is an "orphan disease." The Company has completed a 331-patient Phase III trial of DCVax-L for GBM, presented the results in scientific meetings, published the results in JAMA Oncology and submitted a MAA for commercial approval in the UK. The MAA is currently undergoing review. The Company has also developed DCVax^®-Direct for inoperable solid tumor cancers. It has completed a 40-patient Phase I trial and plans to pursue Phase II trials this year. The Company previously conducted a Phase I/II trial with DCVax-L for advanced ovarian cancer together with the University of Pennsylvania.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning plans for DCVax^® are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "design," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those projected in any forward-looking statement. Readers should not rely upon forward-looking statements. There are a number of important factors that could cause actual results to differ materially from those anticipated, including, without limitation, risks related to delays or uncertainties in regulatory processes and decisions, risks related to the Company's ability to achieve timely performance of third parties, risks related to whether the Company's products will be viewed as demonstrating safety and efficacy, risks related to the Company's ongoing ability to raise additional capital, and other risks included in the Company's Securities and Exchange Commission ("SEC") filings. Additional information on the foregoing risk factors and other factors, including Risk Factors, which could affect the Company's results, is included in its SEC filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual plans, results or timelines to differ materially from those projected in any forward-looking statement. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

CONTACTS

Northwest Biotherapeutics
Dave Innes 
804-513-6758 
dinnes@nwbio.com